NEO KUMA Ventures, the UK’s first investment fund dedicated solely to psychedelic healthcare, has today (3rd June) announced its investment in seven innovative healthcare companies.
The largest placebo-controlled psychedelics study to date concluded that the psychological benefits of microdoses of psychedelics are likely due to the placebo effect.
A research center that will assess the use of psychedelic drugs to treat conditions such as addiction, alcoholism, and depression was announced by Johns Hopkins University.